Business
Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026
DALLAS, May 11, 2026--Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026
About this update from Lantern Pharma Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/08888de7c709be62fabd9aead1100d5b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ehIlgoDWREQmyskLX1XRLg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk2MA--/https://media.zenfs.com/en/business-wire.com/08888de7c709be62fabd9aead1100d5b","width":480,"height":480},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/qBrLd4mCCLmR9hiPP6kK7A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTY0MA--/https://media.zenfs.com/en/business-wire.com/08888de7c709be62fabd9aead1100d5b","width":480,"height":480}},"lazy":false},{"type":"text","content":"DALLAS, May 11, 2026--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company developing targeted and transformative cancer therapies using its proprietary AI and machine learning platforms with multiple clinical stage drug programs, today announced that it will report its first quarter 2026 operating and financial results via press release to be issued on Friday, May 15.","length":425,"tagName":"p"},{"type":"text","content":"The press release will discuss financial results for the first quarter ended March 31, 2026 and provide operational updates on clinical trials and the development of the Company’s AI platforms.","length":193,"tagName":"p"},{"type":"text","content":"About Lantern Pharma","length":20,"tagName":"p"},{"type":"text","content":"Lantern Pharma (NASDAQ: LTRN) is a clinical-stage AI-driven precision oncology company transforming the cost, pace, and timeline of oncology drug discovery and development. The company’s proprietary AI and machine learning platform, RADR®, now operationalized through withZeta.ai, leverages billions of data points and advanced computational methods to rapidly uncover biomarker signatures and accelerate the development of targeted oncology therapies for difficult-to-treat cancers, including those of the central nervous system. Lantern is currently advancing a pipeline of small molecule drug candidates and an antibody-drug conjugate program focused on multiple solid tumor and hematologic malignancies. For more information, visit www.lanternpharma.com. For more information, visit:","length":787,"tagName":"p"},{"type":"list","items":[{...